Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations

Science Translational Medicine(2024)10.1126/scitranslmed.adi0979Source: DataRank Database

An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations is a research paper published in Science Translational Medicine (2024). On theSindex it has a DataRank of 0. It has been cited 43 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access43 citations

Download PDF

Cite:

Linked data & code

pdb doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 13.17)OA: goldTopics (26)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (22)

Yichi Su ORCID,Xinzhi Zou ORCID,Pinghan Huang ORCID,Arjun Rustagi ORCID,Jaishree Garhyan ORCID

Live enrichment

PubMed:38478629 PMC:PMC11193659 OpenAlex:https://openalex.org/W4392763383

NIAID NIH HHS

Grant: U19 AI171421

NIAID NIH HHS

Grant: R01 AI158569

NIGMS NIH HHS

Grant: P30 GM133894

NIAID NIH HHS

Grant: T32 AI007502

Novo Nordisk Fonden

Grant: NNF18OC0031816

FWCI

13.17

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

goldLicense: other-oa

https://pure.au.dk/portal/en/publications/d11c0c31-ac1c-4ee2-a3ea-38a0422d4382

publisherhttps://www.science.org/doi/pdf/10.1126/scitranslmed.adi0979

journalhttps://doi.org/10.1126/scitranslmed.adi0979

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38478629

Fields of Study

SARS-CoV-2 and COVID-19 ResearchHepatitis C virus researchComputational Drug Discovery Methods

MeSH Terms

COVID-19SARS-CoV-2Coronavirus 3C ProteasesAntiviral AgentsHumansMutationProtease Inhibitors

Keywords

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)BioavailabilityProtease inhibitor (pharmacology)Pharmacology2019-20 coronavirus outbreakProteaseSensitivity (control systems)VirologyMedicineChemistryEnzymeBiochemistryViral loadInternal medicineVirus

Sustainable Development Goals

SDG 0: Good health and well-being